Altogether, these factors contribute to treatment inefficiency and patient dissatisfaction
Safety, tolerability, pharmacodynamics and pharmacokinetics of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in healthy subjects
GI effects are common
Ozempic often used off-label) Tirzepatide (Zepbound / Mounjaro) a dual GLP-1/GIP agonist that tends to produce even greater weight loss Liraglutide (Saxenda) Originally developed for Type 2 diabetes, these medications received Health Canada approval for chronic weight management in adults with a BMI 30, or BMI 27 with at least one weight-related condition (such as hypertension, dyslipidemia, or obstructive sleep apnea)
Microbial ecology: Human gut microbes associated with obesity
A recent retrospective cohort also observed that, even in overweight patients without diabetes, the risk of primary open-angle glaucoma and ocular hypertension were significantly lower in the GLP-1RA group at both 3 and 5 years of follow-up (Vasu et al., 2025), suggesting the benefit of GLP-1RAs in the eye as an independent factor apart from blood glucose control
